Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834 - 46; http://dx.doi.org/10.1038/nrc2256; PMID: 17957189
   PubMed Web of Science ®Google Scholar
• Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294:139 - 46; http://dx.doi.org/10.1016/j.canlet.2010.03.004; PMID: 20363069
   PubMed Web of Science ®Google Scholar
• Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012; 18:645 - 53; http://dx.doi.org/10.1158/1078-0432.CCR-11-2186; PMID: 22156560
   PubMed Web of Science ®Google Scholar
• Gilead A, Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1999; 1:226 - 30; http://dx.doi.org/10.1038/sj.neo.7900032; PMID: 10935477
   PubMedGoogle Scholar
• Wu X, Liang L, Dong L, Yu Z, Fu X. Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro. Mol Biol Rep 2013; 40:2671 - 8; http://dx.doi.org/10.1007/s11033-012-2353-x; PMID: 23247805
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005; 7:748 - 60; http://dx.doi.org/10.1593/neo.05289; PMID: 16207477
   PubMed Web of Science ®Google Scholar
• Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, Scarpa A. Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. Neoplasia 2007; 9:181 - 3; http://dx.doi.org/10.1593/neo.06838; PMID: 17401457
   PubMed Web of Science ®Google Scholar
• Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC Jr.. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 2004; 10:6559 - 66; http://dx.doi.org/10.1158/1078-0432.CCR-04-0698; PMID: 15475444
   PubMed Web of Science ®Google Scholar
• Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr., et al. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 2003; 9:3660 - 6; PMID: 14506155
   PubMed Web of Science ®Google Scholar
• Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999; 96:214 - 9; http://dx.doi.org/10.1073/pnas.96.1.214; PMID: 9874798
   PubMed Web of Science ®Google Scholar
• Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr.. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008; 112:1489 - 502; http://dx.doi.org/10.1002/cncr.23323; PMID: 18286529
   PubMed Web of Science ®Google Scholar
• Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9:R57; http://dx.doi.org/10.1186/bcr1762; PMID: 17764565
   PubMed Web of Science ®Google Scholar
• Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC Jr., Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 2003; 12:1791 - 800; http://dx.doi.org/10.1093/hmg/ddg204; PMID: 12874100
   PubMed Web of Science ®Google Scholar
• Hisatomi H, Nagao K, Wakita K, Kohno N. ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis. Oncology 2002; 62:136 - 40; http://dx.doi.org/10.1159/000048259; PMID: 11914599
   PubMed Web of Science ®Google Scholar
• Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, et al. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 2003; 983:268 - 77; http://dx.doi.org/10.1111/j.1749-6632.2003.tb05981.x; PMID: 12724231
   PubMed Web of Science ®Google Scholar
• Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, et al. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 2003; 63:4174 - 80; PMID: 12874023
   PubMed Web of Science ®Google Scholar
• Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 2006; 12:2404 - 13; http://dx.doi.org/10.1158/1078-0432.CCR-05-1036; PMID: 16638845
   PubMed Web of Science ®Google Scholar
• Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003; 22:2897 - 909; http://dx.doi.org/10.1038/sj.onc.1206380; PMID: 12771940
   PubMed Web of Science ®Google Scholar
• Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, et al. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 2012; 31:68 - 79; http://dx.doi.org/10.1038/onc.2011.213; PMID: 21643014
   PubMed Web of Science ®Google Scholar
• Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008; 118:3917 - 29; PMID: 19033662
   PubMed Web of Science ®Google Scholar
• Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG. Angiogenic potential in vivo by Kaposi’s sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994; 8:1237 - 44; http://dx.doi.org/10.1097/00002030-199409000-00004; PMID: 7528513
   PubMed Web of Science ®Google Scholar
• Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, Hlatky L, Vajkoczy P, Huber PE, Folkman J, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69:836 - 44; http://dx.doi.org/10.1158/0008-5472.CAN-08-2590; PMID: 19176381
   PubMed Web of Science ®Google Scholar
• Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400 - 13; http://dx.doi.org/10.1038/sj.onc.1205651; PMID: 12154403
   PubMed Web of Science ®Google Scholar
• Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B, Apte SS. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 1996; 74:853 - 62; http://dx.doi.org/10.1139/o96-090; PMID: 9164653
   PubMed Web of Science ®Google Scholar
• Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9:407 - 15; http://dx.doi.org/10.1038/nm846; PMID: 12652295
   PubMed Web of Science ®Google Scholar
• Pedrazzani C, Corso G, Marrelli D, Roviello F. E-cadherin and hereditary diffuse gastric cancer. Surgery 2007; 142:645 - 57; http://dx.doi.org/10.1016/j.surg.2007.06.006; PMID: 17981184
   PubMed Web of Science ®Google Scholar
• Pinheiro H, Carvalho J, Oliveira P, Ferreira D, Pinto MT, Osório H, Licastro D, Bordeira-Carriço R, Jordan P, Lazarevic D, et al. Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Hum Mol Genet 2012; 21:4253 - 69; http://dx.doi.org/10.1093/hmg/dds248; PMID: 22752307
   PubMed Web of Science ®Google Scholar
• Yi Kim D, Kyoon Joo J, Kyu Park Y, Yeob Ryu S, Soo Kim H, Kyun Noh B, Hwa Lee K, Hyuk Lee J. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis. J Surg Oncol 2007; 96:429 - 35; http://dx.doi.org/10.1002/jso.20732; PMID: 17786966
   PubMed Web of Science ®Google Scholar
• Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41 - 8; http://dx.doi.org/10.1038/71517; PMID: 10613822
   PubMed Web of Science ®Google Scholar
• Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 2011; 22:2423 - 35; http://dx.doi.org/10.1091/mbc.E11-04-0306; PMID: 21613543
   PubMed Web of Science ®Google Scholar
• Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006; 98:1443 - 4; http://dx.doi.org/10.1093/jnci/djj447; PMID: 17047192
   PubMed Web of Science ®Google Scholar
• Thompson CA. Vorinostat approved for rare lymphoma. Am J Health Syst Pharm 2006; 63:2168; http://dx.doi.org/10.2146/news060020; PMID: 17090730
   PubMed Web of Science ®Google Scholar
• Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr.. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011; 117:4424 - 38; http://dx.doi.org/10.1002/cncr.26073; PMID: 21491416
   PubMed Web of Science ®Google Scholar
• Hellebrekers DM, Jair KW, Viré E, Eguchi S, Hoebers NT, Fraga MF, Esteller M, Fuks F, Baylin SB, van Engeland M, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5:467 - 75; http://dx.doi.org/10.1158/1535-7163.MCT-05-0417; PMID: 16505122
   PubMed Web of Science ®Google Scholar
• Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7:437 - 43; http://dx.doi.org/10.1038/86507; PMID: 11283670
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12 - 27; http://dx.doi.org/10.1016/j.cell.2012.06.013; PMID: 22770212
   PubMed Web of Science ®Google Scholar
• Shinojima T, Yu Q, Huang SK, Li M, Mizuno R, Liu ET, Hoon DS, Lessard L. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics 2012; 7:1279 - 89; http://dx.doi.org/10.4161/epi.22333; PMID: 23023649
   PubMed Web of Science ®Google Scholar
• Pesta M, Kulda V, Topolcan O, Safranek J, Vrzalova J, Cerny R, Holubec L. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC. Anticancer Res 2009; 29:4535 - 9; PMID: 20032402
   PubMed Web of Science ®Google Scholar
• Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 2010; 20:623 - 31; http://dx.doi.org/10.1111/j.1750-3639.2009.00340.x; PMID: 19922547
   PubMed Web of Science ®Google Scholar